Oncology Cell & Gene Therapy CRO
Support for complex oncology cell & gene therapy development
Worldwide helps sponsors plan and run oncology cell and gene therapy trials with support built for complex logistics, acute safety oversight, and long-term follow-up across global programs.
Tell us about your study
We’ll connect you with the right oncology clinical
development team.
Your Oncology Cell & Gene Therapy Trial Challenges
Why Oncology Cell & Gene Therapy Needs Different Support
Oncology cell and gene therapy programs involve significantly greater operational and clinical complexity than many traditional oncology studies. Efficient study execution often requires coordinating cell collection, manufacturing, logistics, infusion, monitoring, and follow-up in a setting where timing is critical to both patient outcomes and study continuity. Challenges such as acute toxicities, limited site capacity, manufacturing delays, and long-term follow-up requirements can all add pressure. Related genetically modified modalities, including gene therapy and oncolytic viruses, introduce similar demands around regulatory planning, product handling, safety oversight, and endpoint strategy. Worldwide supports sponsors in navigating these demands through oncology-focused execution, cross-functional support, and experience built around programs where logistics, safety, and timing must be carefully aligned.
Living Products Change Study Execution
In oncology cell and gene therapy, collection, manufacturing, logistics, and infusion must stay tightly coordinated. Worldwide helps sponsors manage these linked steps with operational oversight designed for studies where delays can impact both treatment timing and study continuity.
Safety Oversight Needs Specialized Experience
Cell and gene therapy studies can bring high-acuity events such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and tumor lysis syndrome (TLS). Worldwide supports the monitoring, coordination, and hospitalization-aware execution required to manage these complex safety demands.
Site Readiness Can Shape Trial Feasibility
Cell and gene therapy trials may require sites equipped with apheresis capabilities, robust product handling processes, ICU access, and established toxicity management protocols. Worldwide helps identify and support sites ready to meet these specialized needs.
Long-Term Follow-Up Adds Ongoing Complexity
Cell and gene therapy trials require ongoing engagement beyond infusion. Worldwide supports sponsors with planning that accounts for long-term follow-up, sustained safety monitoring, and evolving resourcing demands over time.
Partnership & Approach
A Cross-Functional Model for Complex Oncology Cell & Gene Therapy Programs
Worldwide partners closely with sponsors to coordinate the scientific, regulatory, medical, operational, site, and vendor demands that shape oncology cell and gene therapy trials. Our teams help align study-specific planning with the realities of product handling, patient monitoring, and execution risk, so programs stay grounded in the needs of both sites and patients at every stage.
Studies in
the Past 5 Years
Patients Enrolled
Unique Sites
Why Worldwide
What Makes Worldwide the Right Oncology Cell & Gene Therapy Fit?
Worldwide brings the operational focus, oncology-specific support, and cross-functional coordination sponsors need for cell and gene therapy programs where complexity is built into the study from the beginning.
Built for Complex Logistics
Oncology cell and gene therapy programs rely on precise coordination of product movement and timing. Worldwide supports chain of custody, chain of condition, chain of identity (when applicable), study-specific handling plans, and seamless coordination across cell collection, manufacturing, shipping, and treatment workflows.
Ready for High-Acuity Safety Demands
These studies require intensive monitoring, rapid escalation pathways, and teams that understand how safety events impact study conduct. Worldwide supports sponsors with execution with a focus on acute toxicity management and hospitalization requirements.
Experience Across Cell Therapy Approaches
Worldwide supports both autologous and allogeneic development approaches across hematologic malignancies and solid tumors, offering sponsors teams that are experienced in the distinct operational nuances of each modality.
Support Across Program Stages
From first-in-human through pivotal trials and long-term follow-up, Worldwide provides continuity, helping sponsors navigate evolving operational complexity as programs advance.
Aligned with Broader Cell & Gene Therapy Complexity
Worldwide’s broader cell and gene therapy expertise helps oncology sponsors plan for added regulatory, handling, safety, and endpoint complexity associated with gene therapies, oncolytic viruses, or other genetically modified approaches.
Services & Capabilities
Comprehensive Oncology CRO Services
- Protocol Design and Clinical Development Planning
- Regulatory Consulting and Global Submissions
- Global Project Management
- Feasibility Analysis and Site Selection Strategy
- Site Initiation and Study Start-up
- Patient Enrollment
- Dose Escalation, Optimization and Cohort Management
- Site Monitoring and Management
- Data Management
- Clinical Data Analytics and Review
- Clinical Science
- Biostatistics
- Medical Monitoring
- Safety / Pharmacovigilance
- Medical Writing
Cell Logistics Orchestration
Worldwide helps sponsors coordinate collection, manufacturing, shipping, handling, and treatment workflows for oncology cell therapy studies where timing, traceability, and product integrity are critical.
Safety Monitoring & Medical Oversight
Our teams support studies that require close attention to CRS, ICANS, TLS, and other acute adverse events, with operational planning built around rapid communication and continuous patient monitoring.
Regulatory & Startup Support
Worldwide helps sponsors plan for the additional regulatory and startup demands these studies can bring, including site readiness, product handling requirements, and study-specific operational workflows.
Program Continuity Through Follow-Up
From first-in-human through pivotal and long-term follow-up, Worldwide supports oncology cell and gene therapy programs with execution that adapts as study requirements evolve.
What Our Clients Say
“I am very happy with the performance of Worldwide and I plan to recommend them to be one of our preferred service providers. Things are going well on our studies and the Worldwide team is performing above our expectations.”
Director of Clinical Pharmacology and Development – Late Phase | Mid-size Pharmaceutical Customer
FAQ & Insights
What Sponsors Need to Know
These programs often involve living or genetically modified products, tightly coordinated handling and logistics, acute safety risks, and extended long-term follow-up obligations. Sponsors may be managing collection, manufacturing, shipping, infusion, monitoring, and post-treatment surveillance in one program, which creates more operational interdependence than many other oncology trials.
Worldwide supports oncology cell therapy studies with tailored logistics planning, detailed handling procedures, and close coordination across sites, vendors, and study teams. This includes attention to chain of custody, chain of identity, chain of condition, along with operational controls needed to ensure patient-specific products move through each step as planned.
Worldwide supports sponsors with execution built around high-acuity monitoring and fast coordination if serious events occur. For cell therapy studies, that includes planning around CRS, ICANS, TLS, hospitalization workflows, and the communication needs that come with time-sensitive safety oversight.
Worldwide supports both autologous and allogeneic cell therapy programs globally across hematologic malignancies and solid tumors. This experience helps sponsors to work with teams who understand how product flow, site readiness, patient timing, and operational complexity can vary between approaches.
Yes. Long-term follow-up is a core component of cell and gene therapy development. Worldwide supports sponsors with planning and execution that account for the operational, safety, and resourcing demands that extend well beyond the initial treatment.
While this page largely focuses on oncology cell therapy, a reflection of historical trends in oncology CGT development, Worldwide also has experience with viral-vectored gene therapy, oncolytic viruses, and other genetic medicine modalities of oncology development. This is a rapidly evolving space — we understand the complexities of regulatory planning, product handling, safety oversight across modalities. Sponsors looking for broader modality detail can also explore Worldwide’s Cell and Gene Therapy expertise.
With sites across North America, Europe, Asia-Pacific, Latin America, and the Middle East and North Africa, Worldwide helps sponsors identify sites equipped for the realities of oncology cell and gene therapy studies, including handling requirements, safety protocols, and specialized operational workflows. That support helps sponsors plan around feasibility, readiness, and execution risk early in the study.
Insights
Explore Our Cell and Gene Therapy Trial Insights
Oncology Expertise
Looking for Other Oncology Specializations?
See what Worldwide Clinical Trials can do for you.
Your study has unique goals, risks, and decisions ahead. Tell us a little about your needs, and our team will connect you with the right Worldwide experts to discuss how our scientific, medical, and operational support can help move your program forward with confidence.
